LSZ

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
5. 2026-09-07srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
6. 2026-09-07srcAnalytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ)
7. 2026-09-07srcA Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
8. 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
9. 2026-09-07srcDesigner drugs: mechanism of action and adverse effects
10. 2026-09-07srcPharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)
11. 2026-09-07srcSerotonin toxicity of serotonergic psychedelics
12. 2026-09-07srcIn vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
13. 2026-09-07srcIdentification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products
14. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
15. 2026-09-07srcChronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans.
16. 2026-09-07srcA non-hallucinogenic LSD analog with therapeutic potential for mood disorders
17. 2026-09-07srcThe polypharmacology of psychedelics reveals multiple targets for potential therapeutics
18. 2026-09-07srcAn animal model of schizophrenia based on chronic LSD administration: old idea, new results
19. 2026-09-07srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
20. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
21. 2026-09-07srcAcute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
22. 2026-09-07srcDirect comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
23. 2026-09-07srcPsychedelics promote plasticity by directly binding to BDNF receptor TrkB
24. 2026-09-07srcClassic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures
25. 2026-09-07srcKetanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
26. 2026-09-07srcPharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
27. 2026-09-07srcAdverse effects of psychedelics: From anecdotes and misinformation to systematic science
28. 2026-09-07srcDrug-drug interactions involving classic psychedelics: A systematic review
29. 2026-09-07srcSerotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
30. 2026-09-07srcMechanism of tolerance development to 2,5-dimethoxy-4-iodoamphetamine in rats: down-regulation of the 5-HT2A, but not 5-HT2C, receptor
31. 2026-09-07srcLysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)
32. 2026-09-07srcNew-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case Study
33. 2026-09-07srcComa, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases.
34. 2026-09-07srcLSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
35. 2026-09-07srcDetails for Lysergamides - UNODC Laboratory and Scientific Service
36. 2026-09-07srcLysergic acid 2,4-dimethylazetidide - HandWiki
37. 2026-09-07srcPsychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
38. 2026-09-07srcLSZ Legal Status - Erowid
39. 2026-09-04issueIssued emergency
40. 2026-09-04issueIssued info_card
41. 2026-09-04issueIssued notice
42. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
43. 2026-06-04publicationPublication — backfill
44. 2026-04-26revisionRevision 1
45. 2026-04-26absenceSearched ClinicalTrials.gov for "LSZ lysergamide psychedelic" — no results
46. 2026-04-26absenceSearched PubChem for "LSZ lysergamide" — no results
47. 2026-04-26genGeneration — pipeline-v5 · with 2 morepipeline-v5
48. 2026-04-26rungeneration run

The same entries, as forms: six forms.